You can buy or sell CLBS and other stocks, options, ETFs, and crypto commission-free!
Caladrius Biosciences, Inc. Common Stock, also called Caladrius Biosciences, is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Read More Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Basking Ridge, New Jersey
52 Week High
52 Week Low
Yahoo FinanceMay 24
Edited Transcript of CLBS earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Caladrius Biosciences Inc Earnings Call New York May 24, 2019 (Thomson StreetEvents) -- Edited Transcript of Caladrius Biosciences Inc earnings conference call or presentation Thursday, May 9, 2019 at 8:30:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * David J. Mazzo Caladrius Bioscie...
Seeking AlphaMay 9
Caladrius Biosciences, Inc.'s CEO David Mazzo on Q1 2019 Earnings Conference Call Transcript
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q1 2019 Results Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants John Menditto - VP IR & Corporate Communications David Mazzo - President & CEO Joseph Talamo - SVP & CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright Steve Brozak - WBB Securities Jason Kolbert - Dawson James Securities Pete Enderlin - MAZ Partners Keay Nakae - Chardan Securities Operator Welcome to the Caladrius Biosciences First Quarter 2019 Financia...
Yahoo FinanceMay 9
Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update
All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively CLBS14-NORDA phase 3 program targeted to begin enrollment in late 2019 Cash on hand projected to support existing programs through 2Q2020 Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceut...
Expected Aug 8, After Hours